600 results about "Dihydropyridine" patented technology

Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound is an ophthalmic or dermal wound, such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers include olopatadine, variants of olopatadine, alcaftidine, derivatives of alcaftidine, dihydropyridines, and spleen tyrosine kinase inhibitors.

The present invention provides compounds of Formula (I):

or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

This invention relates to dihydropyridine compounds of formula (I):

or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein A₂, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₁₉, R₂₀, R₂₁, R₂₂, and m are defined herein, and compositions comprising such compounds. The invention also relates to methods of preventing or treating metabolic disorders, such as diabetes mellitus, and conditions and complications associated with diabetes mellitus, comprising administering to a subject in need thereof a compound of formula (1) or a composition comprising such a compound. The invention further relates to kits comprising a compound of formula (I).

The present invention relates to a therapeutic agent for dyskinesia excluding tremor, comprising 1,2-dihydropyridine compound, a salt thereof, or a solvate thereof, which shows AMPA receptor antagonism and is highly useful as a pharmaceutical drug.

The invention provides a feed additive for improving the quality of the fur of a furry animal. The additive is obtained by mixing a semi-finished vitamin product, a semi-finished trace element product, dihydropyridine, methionine, cystine and corn gluten meal according to a weight ratio of 1:1:0.3-1:0.2-0.9:0.1-0.6:2, wherein the semi-finished vitamin product is prepared by uniformly mixing the following components: 5-22 parts of vitamin A, 3-8 parts of vitamin D, 10-25 parts of vitamin E, 3-8 parts of vitamin B1, 8-15 parts of biotin, 1-3 parts of vitamin B6, and 120-160 parts of the corn gluten meal, and the semi-finished trace element product is prepared by uniformly mixing the following components: 10-20 parts of methionine chelated zinc, 2-5 parts of methionine chelated copper, and 70-90 parts of zeolite powder. The additive of the invention allows the quality of the fur of the furry animals (martens, foxes and raccoon dogs) to be substantially improved, the hair density to be increased, the hair length to be improved, the hide toughness to be increased and the culture benefit to be improved.

The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine<CUSTOM-CHARACTER FILE="US06440933-20020827-P00900.TIF" ALT="custom character" HE="20" WI="20" ID="CUSTOM-CHARACTER-00001"/>pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

The invention relates to a premix for improving the reproductive performance of fur animals, comprising trace element semi-finished product and a vitamin semi-finished product. The trace element semi-product is prepared from the following components: 10-40 parts of amino acid Fe-chelate, 10-50 parts of amino acid zinc chelate, 20-40 parts of amino acid manganese chelate, 5-20 parts of amino acid copper chelate, 1-8 parts of amino acid selenium chelate and 125-135 parts of zeolite powder; the vitamin semi-finished product is prepared from the following components: 2-8 parts of vitamin A, 1-4 parts of vitamin D, 15-35 parts of vitamin E, 30-70 parts of dihydropyridine, 10-20 parts of methionine and 100-125 parts of corn protein powder; and the two semi-products are uniformly mixed accordingto the ratio of 1: 1 to obtain the final product. The premix is applicable to a hybridization preparation period, a gestation period and a lactation period of foxes, minks and raccoons. By feeding the premix provided by the invention, reproductive performance of foxes, minks and raccoons, oestrus rate, conception rate, number born and survival rate of weaning cubs can be improved.

A photosensitive resin composition contains a component (A) and at least one of a component (B) and a component (C). In addition, in the circuit board with metal support including: a metal support; a base insulating layer; a conductive layer formed of a wiring circuit pattern; and a cover insulating layer, at least one of the above-mentioned base insulating layer and cover insulating layer is made of the above-mentioned photosensitive resin composition.

• (A) a 1,4-dihydropyridine derivative represented by the following general formula (1)

where R₁ represents an alkyl group having 1 to 3 carbon atoms; and R₂ and R₃ each represent a hydrogen atom or an alkyl group having 1 or 2 carbon atoms and may be identical to or different from each other;

• (B) the following (x) and (y):
  • (x) a carboxyl group-containing linear polymer; and
  • (y) an epoxy resin
• (c) a linear polymer having a carboxyl group and an epoxy group

The present invention relates to a novel process for the preparation of 1-alkyl or 1-cycloalkyl derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxamide of formula I. The process includes reacting an amine R²NH₂ with a compound of formula II in a solution of metal hydroxide in water to give a compound of formula III. Subsequent reaction of the compound of formula III with an acid chloride formation reagent in an inert solvent gives compounds of formula I. The acid chloride formation reagent is selected from oxalyl chloride and dimethylformamide, dimethylchloromethylene-ammonium chloride and thionyl chloride and dimethylformamide. If desired, a compound of formula I where R⁵ is hydrogen may be formed when an intermediate substituent is used wherein R⁵ is an alcohol protective group removable by catalytic hydrogenation.

The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

Combinations of one or more dihydropyridine calcium channel blockers with mixtures of omega-3 fatty acids, methods of administering such combinations, and unit dosages of such combinations.

A carbon quantum dot based on a copper complex and a preparing method thereof are disclosed. Copper disodium ethylenediaminetetraacetate having a saturated Schiff base structure is adopted as a raw material, the copper complex and a carbon quantum dot having a structure similar to that of graphene are composited, and the carbon quantum dot based on the copper complex is prepared by a thermo-polymerization method so as to improve electron transfer capability of photosensitizers of this type. The prepared carbon quantum dot based on the copper complex is good in water solubility, electron receptivity, electron releasing capability and electrical conductivity and wide in visible-light response range, and is an excellent photosensitizer. By application of the photosensitizer into a photooxidation reaction of 1,4-dihydropyridine, efficient photo-catalytic oxidation of reactions of this type is achieved and byproducts only comprise water and oxygen.

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

A photosensitive polyimide resin precursor composition capable of providing a polyimide resin that is not substantially colored, is transparent and has heat resistance, an optical polyimide resin obtained from the composition, and an optical waveguide using the polyimide resin. The photosensitive polyimide resin precursor composition contains (a) 100 parts by weight of a polyamic acid obtained from a tetracarboxylic acid dianhydride and a diamine, (b) 0.01 parts by weight or more and less than 5 parts by weight of a 1,4-dihydropyridine derivative, (c) 5-50 parts by weight of a glycol (ether). The optical polyimide resin is obtained by irradiating the photosensitive resin precursor composition with UV light, followed by exposure, heating, development, and then heating. The optical waveguide comprises a core layer comprising the optical polyimide resin, and a cladding layer thereof.

The invention provides 5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one compounds that are selective inhibitors of KDR and FGFR kinases, and are useful in the treatment of cancers. The compounds have the generic structure I

where Ar, Ar′, and R¹ are as set forth in the present specification. The invention also provides pharmaceutical compositions containing these compounds and methods for their use.

The invention discloses a method for asymmetric synthesis of levorotation menthol. The method comprises the following steps: citral is taken as an initial raw material, a dihydropyridine derivant is taken as a negative hydrogen source, chiral amine serves as a chiral auxiliary agent for catalytic and asymmetric hydrogenization synthesis of dextrorotation citronellal, the dextrorotation citronellal is catalyzed by Lewis acid for ring-closing synthesis of levorotation isopulegol, and the levorotation isopulegol is subject to catalytic hydrogenation to finally produce the levorotation menthol. The total yield of the levorotation menthol produced by adopting the method is larger than 60 percent, and the ee (enantiomeric excess) value is larger than 90 percent. The method has the characteristics of mild reaction conditions, simple synthetic process, simplicity in catalyst preparation, convenience in catalyst recovery and the like and is suitable for large-scale industrial production of levorotation menthol.

Provided are methods for reducing intraocular pressure in an individual having an ocular disorder causing elevated intraocular pressure, such as glaucoma. The method comprises administering to the individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A₃ subtype adenosine receptor (A₃AR) antagonist, including dihydropyridine, pyridine, pyridinium salt or triazoloquinazoline, and derivatives thereof expressly having A₃AR antagonist activity, including, e.g., the nucleoside-based A₃AR antagonist, MRS-3820. Further provided is a method for ensuring the delivery of a topically administered therapeutic composition for reducing intraocular pressure, wherein the method expressly requires physically opening a channel through the corneal barrier of the patient's eye by a microneedle or micropipette to permit transport of the topical composition to the anterior chamber of the eye.

The present invention provides a peripheral ocular circulation ameliorant which contains dihydropyridines represented by the general formula (I) or their medicinally acceptable salts as active ingredients(where R1 is a nitrophenyl group and R2, R3, and R4 are lower alkyl groups), and particularly provides an optic disc blood flow ameliorant, choroidal blood flow ameliorant, retinal blood flow ameliorant, and accordingly, therapeutics for visual field defects associated with normal intraocular pressure glaucoma as well as for optic neuropathy, retinopathy, retinal-degeneration diseases, etc.